Clindamycin vs. first-generation cephalosporins for acute osteoarticular infections of childhood-a prospective quasi-randomized controlled trial  by Peltola, H. et al.
Clindamycin vs. ﬁrst-generation cephalosporins for acute osteoarticular
infections of childhood—a prospective quasi-randomized controlled trial
H. Peltola1, M. Pa¨a¨kko¨nen2, P. Kallio1, M. J. T. Kallio1 and The OM-SA Study Group*
1) Children’s Hospital, Helsinki University Central Hospital, and University of Helsinki and 2) Turku University Central Hospital, Turku, Finland
Abstract
No sufﬁciently powered trial has examined two antimicrobials in acute osteoarticular infections of childhood. We conducted a prospec-
tive, multicentre, quasi-randomized trial in Finland, comparing clindamycin with ﬁrst-generation cephalosporins. The age of patients
ranged between 3 months and 15 years, and all cases were culture-positive. We assigned antibiotic treatment intravenously for the ﬁrst
2–4 days, and continued oral treatment with clindamycin 40 mg/kg/24 h or ﬁrst-generation cephalosporin 150 mg/kg/24 h in four doses.
Surgery was kept to a minimum. Subsiding symptoms and signs and normalization of C-reactive protein (CRP) level were preconditions
for the discontinuation of antimicrobials. The main outcome was full recovery without further antimicrobials because of an osteoarticu-
lar indication during 12 months after therapy. The intention-to-treat analysis comprised 252 children, 169 of whom were analysed
per-protocol: 82 cases of osteomyelitis, 80 of septic arthritis, and seven of osteomyelitis–arthritis. Staphylococcus aureus strains (all meth-
icillin-sensitive) caused 84% of the cases. Except for one non-serious sequela during convalescence in both groups, and two late infec-
tions caused by dissimilar agents in one child, all patients recovered. The entire courses (medians) of clindamycin and cephalosporin
lasted for 23 and 24 days, respectively. CRP normalized in both groups in 9 days. The patients were discharged, on average, on day 10.
Loose stools were reported less often (1%) in the clindamycin group than in the cephalosporin group (7%), but two clindamycin recipi-
ents developed rash. Clindamycin or a ﬁrst-generation cephalosporin, administered mostly orally, perform equally well in childhood
osteoarticular infections, provided that high doses and administration four times daily are used. As most methicillin-resistant staphylo-
cocci remain clindamycin-sensitive, clindamycin remains an option instead of costly alternatives.
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Introduction
No comparative data deriving from a sufﬁciently powered
trial on antimicrobials have previously been available. Clini-
cians have based the treatment of acute childhood osteo-
articular infections—haematogenous osteomyelitis (OM),
septic arthritis (SA), and the osteomyelitis–arthritis (OM–SA)
combination—on retrospective case series, reviews, and
their own experience [1–6]. The two largest series on OM
comprised only 80 [7] and 64 [8] subjects. Also for SA, most
information has been obtained from retrospective, although
sometimes large [4–6], series.
Realizing the need for a large comparative study, we set
up such a trial in Finland, knowing that it would take a long
time because of the rarity of these diseases in an industrial-
ized country. We aimed at identifying a safe, moderately
priced and effective antimicrobial that, after a few days of
intravenous treatment, could be administrated orally without
serum assays; thus, the entire treatment process would
be simpliﬁed and costly hospital stays would be shortened.
Clindamycin and ﬁrst-generation cephalosporins fulﬁlled
our requirements [9–11].
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Patients and Methods
Study design and diagnosis
We treated children born on odd days with clindamycin, and
those born on even days with cephalosporin. A concurrent
randomization assigned the patients to a short (OM, 20 days;
SA, 10 days) or long (30 days regardless of the diagnosis)
course of antimicrobial [12,13]. The study was a multicentre
(seven referral hospitals; see Appendix 2), quasi-randomized,
open-label, parallel-group equivalence trial, which we carried
out in Finland in 1983–2005 [12,13]. The study protocol was
approved by each institution’s ethical committee, and the child
was included only if consent was provided by a legal guardian.
The same form also explained the set-up of the study. We
designed, conducted and analysed the trial independently of
any medical companies or manufacturers, and registered the
trial in an international register (ISRCTN 38832979).
We included previously healthy children aged 3 months to
15 years who presented with an acute osteoarticular infec-
tion—fever, and a painful, tender, warm and swollen bone or
joint area without trauma. We analysed only culture-positive
cases. OM was deﬁned as a case with an agent isolated from
the site, or, if identiﬁed from blood culture, with documenta-
tion of bone involvement by local pus or compatible signs on
radiography or magnetic resonance imaging. In SA and
OM–SA, bacteria were isolated from the site, or, if they
were only isolated from blood, radiological proof of joint
effusion was required.
We kept surgery to a minimum, apart from percutaneous
aspiration or surgical incision to obtain a representative sam-
ple for bacteriology. We did not recommend large corticot-
omy in OM, or repeated aspirations or arthrotomy in SA,
not even in hip [14] or shoulder arthritis, although the
attending orthopaedic or paediatric surgeon had the ﬁnal
decision. Blood culture was performed in all cases.
Treatment
Most osteoarticular infections in industrialized countries are
caused by Gram-positive agents, so we used clindamycin
40 mg/kg/24 h in four doses or a ﬁrst-generation cephalo-
sporin (see below) at 150 mg/kg/24 h in four doses [3,10–
13]. In cases of allergy, we assigned the alternative. As SA
during the early study years was often caused by Haemophilus
inﬂuenzae type b [15], children aged 0–4 years initially also
received ampicillin or amoxycillin, both at 200 mg/kg/24 h in
four doses. Once the aetiology was determined, the course
was completed with one agent only. After H. inﬂuenzae
type b was eliminated by vaccination, we abandoned the use
of ampicillin/amoxycillin in 1997 [16].
Our ﬁrst choice among ﬁrst-generation cephalosporins
was cephradine [9], because it was available for parenteral
and oral use. Its later withdrawal from all of Scandinavia
forced us to change to intravenous cephalothin, and oral
cephalexin or cephadroxil. We did not deem this to be criti-
cal to the study, because all ﬁrst-generation cephalosporins
perform rather similarly, and the dosing is the same. Before
the new alternatives were approved by all participating cen-
tres, we used clindamycin; thereafter, randomization contin-
ued until both arms completed the sample size requirement.
All medications were started intravenously four times
daily, but after 2–4 days they were switched to oral admis-
tration with the same high doses. We did not assay serum
or joint ﬂuid concentrations, or use adjuvant dexamethasone
[17]. The attending clinician (paediatrician, or paediatric or
orthopaedic surgeon) gave non-steroidal anti-inﬂammatory
drugs at his or her discretion.
The attending clinician discontinued the antimicrobial once
the clinical response was found to be good—the patient had
defervesced, and most local symptoms and signs were sub-
siding—and the serum C-reactive protein (CRP) level had
fallen to <20 mg/L [18–21]. If the symptoms and signs were
still prominent, or CRP remained elevated or re-increased
notably, the antimicrobial was continued until two normal
values (extra checks) were obtained.
Follow-up
The preset laboratory and radiographical investigations in
hospital and after discharge comprised a plain radiograph on
admission, and on days 10 and 19, and basic blood analysis at
presentation and on days 5 and 10. We measured CRP [18–
21] and erythrocyte sedimentation rate (ESR) [3,18–21]
throughout the follow-up. A CRP level exceeding 20 mg/L
[18,22] or an ESR of 20 mm/h [3,18] was considered to be
elevated. Computerized tomography and magnetic resonance
imaging were performed on demand. The data were recorded
in special forms, and then computerized and analysed in Hel-
sinki. A researchers’ meeting was held once a year.
Osteoarticular infections sometimes re-occur [4,23,24],
and long-term sequelae may develop slowly [25]. We sched-
uled control visits at 2 weeks and 3 and 12 months
post-hospitalization, and organized extra visits if needed. The
liaison person, a paediatrician or surgeon, performed all
examinations, paying special attention to potential sequelae.
Outcome measures and statistical analysis
The primary endpoint in both the intention-to-treat (ITT)
and per-protocol (PP) analyses was full recovery; that is,
the patient was free of the symptoms or signs of an
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osteoarticular infection, with no antimicrobials being
re-administered for this indication after the treatment course
during the 12-month follow-up. Secondary outcomes
included a comparison of the time to normalization of the
laboratory indices between the clindamycin and cephalospo-
rin recipients, and hospital stay.
Power calculations were performed on the assumption of
a success rate of 95%. In all, 59 patients per group were
required for a power of 80% for detection of a 10% differ-
ence (considered to be clinically meaningful) between groups.
The Newcombe method was applied to calculate the
95% CIs of the difference between proportions. p-Values
were two-sided and not adjusted for multiple analysis. The
level of statistical signiﬁcance was set at a = 0.05.
Results
The series, localization, and causative agents
Two hundred and sixty-ﬁve cases were bacteriologically posi-
tive (Fig. 1). Thirteen were excluded because the clinician
had commenced a non-protocol antimicrobial. Thus, 252
children were included in the ITT analysis (Table 1). Both
antimicrobials were administered intravenously for 3 days
(interquartile range (IR) for a median of 3–4 days). In total,
the patients received clindamycin for 23 days (IR 20–30 days)
and cephalosporin for 24 days (IR 13–30 days). As 83
children were treated entirely with ampicillin/amoxycillin or
with a non-recommended agent, the ﬁnal analysis comprised
169 patients, all of whom had received a full course of clin-
damycin or a ﬁrst-generation cephalosporin. Also included
were the 14 children (six in the clindamycin group and eight
in the cephalosporin group) who, for the ﬁrst few days, had
also been treated with ampicillin. In all, there were 82
children with OM (the three main sites being the femur (24),
tibia (21), and calcaneum (12)), 80 with SA (hip in 27, knee
in 22, and ankle in 20), and seven with OM–SA (affecting
mostly the hip and femur in four).
The two groups were comparable (Tables 1 and 2). There
was a slight preponderance of males, most children were of
school age, medical advice was sought mostly within 3 days,
and SA was slightly more common than OM. OM–SA was
found in <10% of cases.
Staphylococcus aureus, which was invariably susceptible to
methicillin and clindamycin, caused 84% of cases, whereas
Streptococcus pyogenes caused 9% and Streptococcus pneumo-
niae caused 5%. Comparable increases in CRP, ESR and
leukocyte count (Tables 1 and 2) suggested that the disease
severity was similar in the clindamycin and cephalosporin
groups.
Recovery and outcome
The main result of the whole trial was that all 99 of the 99
(95% CI 96.3–100) clindamycin recipients and—if the child
with late re-infections is included—69 of the 70 (98.6%;
95% CI 92.3–99.8) cephalosporin recipients recovered with
the primary treatment. There was one non-serious sequela
in each group.
Table 3 summarizes the results for the 252 patients
included in the ITT analysis (2 · 2 factorial design). Regarding
the clinical response, no major difference was observed
between clindamycin and cephalosporin. In PP analysis, the
CRP peak was reached 1 day sooner in the clindamycin group
(Fig. 2), but the difference remained insigniﬁcant (p 0.13 on
day 3). The groups did not differ signiﬁcantly in the frequency
of surgical procedures (Table 3). Furthermore, CRP and ESR
normalized almost identically, as levels of 20 mg/L and
20 mm/h were reached on day 9 and day 29, respectively
(p 0.47 and p 0.45; Fig. 2). Blood leukocytes normalized in
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FIG. 1. Flow chart. Randomization was performed by contacting a
special ward of the Children’s Hospital (Helsinki, Finland). A com-
puter-generated number was given by telephone. Quasi-randomiza-
tion was performed by birth date. Children born on an odd day
were given clindamycin; children with an even birthday received
ﬁrst-generation cephalosporin.
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5 days. The laboratory indices remained unchanged after the
discontinuation of the antimicrobial (Fig. 2).
The symptoms and signs subsided gradually, and the mean
hospital stay was similar: in ITT analysis, 11 days (±0.5 days)
in the clindamycin group and 12 days (±0.6 days) in the
cephalosporin group (p 0.10). In PP analysis, hospital stay
was the same: 10 days (±0.5 days) for both groups (p 0.75).
Two weeks after discharge, 38% (95% CI 29–48) of clinda-
mycin recipients and 34% (95% CI 24–46) of cephalosporin
recipients had some complaints, but there was no difference
between the groups. At 3 months, three patients showed
some minor symptoms, all of which disappeared in the next
12 months. At the 1-year check-up, one child in each group
had developed symptoms: an 11-year-old boy with perinatal
Erb’s palsy and elbow arthritis showed a mild extension deﬁ-
cit (probably related to previous palsy), and a 14-year-old
boy with hip arthritis had limb shortening of 1 cm. The palsy
remained, but the extension deﬁcit and the shortening
healed within 12 months.
The only child with sequelae in the ITT analysis was a
12-year-old boy with ankle OM–SA who was treated with
intravenous clindamycin for 3 days and oral penicillin for
77 days; this major prolongation of medication was a result
of slow clinical recovery. The patient was excluded from the
PP analysis because of the use of penicillin. At the 1-year
check-up, he complained of pain during exercise, and radio-
graphy identiﬁed joint destruction in the tibiotalar joint.
A 10-year-old boy’s staphylococcal tibiotalar arthritis had
been treated with cephradine for 28 days [12]. Seventeen
months later, the same joint was affected by S. aureus.
Cephradine was re-instituted, but a suboptimal response led
to a change to clindamycin. Again, recovery seemed
uneventful, until coagulase-negative staphylococci re-infected
the same ankle 8 months later. A 30-day course of clinda-
mycin was successful, and since 1990 the child has remained
well. No surgery besides aspiration was carried out. A
scintigram was normal, and no immunodeﬁciency was found.
Also, no cephradine or clindamycin resistance was
encountered.
Drug tolerability
High doses were tolerated well with both agents. Unexpect-
edly, loose stools were reported slightly less often in the
clindamycin group than in the cephalosporin group (1%
(95% CI 0–4) vs. 7% (95% CI 4–14), respectively). Two
clindamycin recipients developed rash.
TABLE 1. Intention-to treat analysis
Total
N = 252
Randomized to:
Clindamycin
N = 141
Cephalosporin
N = 111
Full recovery at the 12-month check-up, no. (%) 249 (99) 139 (99) 110 (99)
Gender, male/female 154/98 81/60 73/38
Age (years), median (IQR) 8 (4–11) 9 (5–12) 7 (3–10)
First symptoms (days), median (IQR) 3 (2–5) 3 (2–5) 3 (1–4)
Type of infection, no. (%)
Osteomyelitis 100 (40) 58 (41) 42 (38)
Septic arthritis 130 (52) 69 (49) 61 (55)
Osteomyelitis + septic arthritis 22 (9) 14 (10) 8 (7)
Causative agent, no. (%)
Staphylococcus aureus 189 (75) 108 (43) 81 (73)
Streptococcus pyogenes 25 (10) 14 (10) 11 (10)
Haemophilus inﬂuenzae type b 24 (10) 14 (10) 10 (9)
Streptococcus pneumoniae 11 (4) 3 (1) 8 (7)
Other 3 (1) 2a (1) 1b (1)
Site from which agent cultured, no. (%)
Joint and blood 41 (16) 23 (16) 18 (16)
Joint only 60 (24) 36 (26) 24 (22)
Bone and blood 33 (13) 17 (12) 16 (14)
Bone only 40 (16) 21 (15) 19 (17)
Blood onlyc 78 (31) 49 (35) 29 (26)
Initial value, mean ± SEM
CRP (mg/L) 87 ± 4 88 ± 4 85 ± 6
ESR (mm/h) 51 ± 2 54 ± 2 46 ± 3
Blood leukocyte count (per mm3) 12 500 ± 400 12 400 ± 500 12 700 ± 700
Treatment completed with ampicillin/amoxycillin or antibiotic outside protocol, no. (%) 83 (33) 42 (30) 41 (37)
Antimicrobials given (days), median (IQR)
Intravenous administration 3 (3–4) 3 (3–4) 3 (3–5)
Total course 24 (17–30) 21 (20–30) 25 (15–30)
Any complaint at the 12-month check-up (see text), no. 3 2 1
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IQR, interquartile range; SE, standard error of the mean.
aStreptococcus group G, Meningococcus group B.
bMeningococcus W 135.
cWith compatible symptoms and signs, and objective evidence of an osteoarticular infection.
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Discussion
Our prospective quasi-randomized study on 169 PP-treated
bacteriologically conﬁrmed cases of acute osteoarticular
infections of childhood is the largest to date, and addresses
the call for a randomized equivalence trial [26]. It also
answers several questions that have been raised over the
years [1,2,5,6].
All patients recovered with an approximately 3-week,
mostly oral, course of clindamycin or a ﬁrst-generation ceph-
alosporin. This ﬁnding is especially relevant to osteoarticular
infections, in which up to one-third of prolonged courses are
interrupted because of adverse events [27].
Clinically, both antimicrobials performed similarly. They
also proved to be safe. Notably, diarrhoea was not a prob-
lem, even in the clindamycin group. Good activity against the
relevant bacteria, and sufﬁcient absorption and tissue pene-
tration [9–11], allow oral administration, provided that
exceptionally large doses are used [11]—we believe that this
and the administration four times daily of these time-depen-
dent antimicrobials are pivotal. No serum assays are needed,
but good adherence to treatment is mandatory. Palatability,
TABLE 2. Per-protocol analysis
Total
N = 169
Randomized to:
Clindamycin
N = 99
Cephalosporin
N = 70
Gender, male/female 102/67 53/46 49/21
Age (years), median (IQR) 9 (6–11) 10 (6–12) 8 (4–11)
First symptoms (days), median (IQR) 3 (2–5) 3 (2–5) 3 (2–4)
Type of infection, no. (%)
Osteomyelitis 82 (49) 50 (51) 32 (46)
Septic arthritis 80 (47) 44 (44) 36 (51)
Osteomyelitis + septic arthritis 7 (4) 5 (5) 2 (3)
Causative agent, no. (%)
Staphylococcus aureus 142 (84) 88 (89) 54 (77)
Streptococcus pyogenes 15 (9) 7 (7) 8 (11)
Streptococcus pneumoniae 9 (5) 3 (3) 6 (9)
Other 3 (2) 1a (1) 2b(3)
Site from which agent cultured, no. (% of total)
Joint and blood 22 (13) 13 (13) 9 (13)
Joint only 41 (24) 23 (23) 18 (25)
Bone and blood 17 (10) 8 (8) 9 (13)
Bone only 26 (16) 13 (13) 13 (19)
Blood onlyc 63 (37) 42 (43) 21 (30)
Initial value, mean ± SEM
CRP (mg/L) 78 ± 4 82 ± 5 73 ± 7
ESR (mm/h) 48 ± 2 51 ± 3 42 ± 3
Blood leukocyte count (per mm3;) 10 900 ± 400 11 000 ± 500 10 800 ± 700
Treatment initiated with ampicillin/amoxycillind, no. (%) 14 (8) 6 (6) 8 (11)
Antimicrobials (days), median (IQR)
Intravenous administration 3 (3–4) 3 (3–3) 3 (3–4)
Total course 24 (20–30) 23 (20–30) 24 (13–30)
Any complaint at the 12-month check-up (see text) 2 1 1
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IQR, interquartile range; SEM, standard error of the mean.
aStreptococcus group G.
bNeisseria meningitidis group B, Haemophilus inﬂuenzae type b.
cWith compatible symptoms and signs, and objective evidence of an osteoarticular infection.
dAmpicillin/amoxycillin, clindamycin or cephalosporin discontinued once agent had been identiﬁed. Children with a full course of ampicillin/amoxycillin (H. inﬂuenzae type b
disease) and those with other medications excluded from analysis.
TABLE 3. Results of the intention-to-treat analysis
(N = 252)
Clindamycin
Cephalosporin
(ﬁrst
generation)
Either
agent
Short treatment
N 69 56 125
Re-infection 0 (0, 0–0)a 0 (0, 0–0) 0 (0, 0–0)
Permanent sequelae 0 (0, 0–0) 1 (0.4, 0–2) 1 (0.4, 0–2)
Invasive surgeryb 23 (33, 23–45) 13 (23, 14–36) 36 (29, 22–37)
Excludedc 21 (8, 6–12) 20 (8, 5–12) 41 (16, 12–21)
Per-protocold 48 (19, 15–24) 36 (14, 10–19) 84 (33, 28–39)
Long treatment
N 72 55 127
Re-infection 0 (0, 0–0) 1 (0.4, 0–2) 1 (0.4, 0–2)
Permanent sequelae 2 (1, 0–3) 0 (0, 0–0) 2 (1, 0–3)
Invasive surgery 18 (25, 16–36) 9 (16, 9–28) 27 (21, 15–29)
Excluded 21 (8, 6–12) 21 (8, 6–12) 42 (17, 13–22)
Per-protocol 51 (20, 16–26) 34 (13, 10–18) 85 (34, 28–40)
Short or long treatment
N 141 111
Re-infection 0 (0, 0–0) 1 (0.4, 0–2)
Permanent sequelae 2 (1, 0–3) 1 (0.4, 0–2)
Invasive surgery 41 (29, 22–37) 29 (26, 19–35)
Excluded 42 (17, 13–22) 41 (16, 12–21)
Per-protocol 99 (39, 33–45) 70 (28, 23–34)
aData given as no. (%, 95% CI).
bSurgical procedures apart from diagnostic sampling (lavation, arthrotomy, or
trepanation of bone).
cExcluded from ﬁnal analysis (ampicillin/amoxycillin or antibiotic outside proto-
col).
dIncluded in the ﬁnal (per-protocol) analysis.
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which is an important issue in paediatrics, is especially good
with cephalosporins. The oral route simpliﬁes treatment and
beneﬁts the patients and personnel. Most oral agents are
also considerably cheaper than their parenteral forms. The
initial intravenous phase can be very short [26] (if needed at
all), and successful treatment is soon reﬂected by declining
CRP (and ESR).
As most methicillin-resistant S. aureus strains have
remained susceptible to clindamycin [28], its good efﬁcacy in
methicillin-susceptible OM–SA is welcome news in these
days of active promotion of costly alternatives, which also
cause more adverse events without providing better effec-
tiveness [7,29,30]. In this trial, two clindamycin recipients
developed rash, but even if a causal association is assumed,
the 2% incidence rate is still tolerable in light of all the
advantages of this moderately priced old remedy.
Our study also had limitations. Unexpected withdrawal of
cephradine led to a temporary overuse of clindamycin.
Enrolment of patients lasted for a long time, because the
incidence of acute OM at age 0–14 years in Finland is merely
4.5 per 100 000 per year [13], and SA is even rarer [12].
We had to choose between diagnostic accuracy—requiring
culture positivity in all cases—or inclusion of less well-docu-
mented cases. We chose the ﬁrst alternative, but had to pay
for our decision with a long enrolment time. However, the
researchers’ yearly meetings kept standards the same over
the years.
We did not detect cases caused by Kingella kingae, which
is compatible with the epidemiology in Finland. If K. kingae is
common, clindamycin monotherapy cannot be used
empirically.
Some patients were treated with antimicrobials that are
not recommended in the protocol, but, importantly, this
never occurred because initial clindamycin or cephalosporin
had failed. We could not always see indication for the devia-
tions, but agree with the ethical view that the clinician
responsible for the patient has the ﬁnal decision. We used
birthdays for quasi-randomization instead of computer-gener-
FIG. 2. Normalization of the serum C-reactive protein (CRP) level (± standard error of the mean) and erythrocyte sedimentation rate (ESR)
and of white blood cell (WBC) count occurred almost identically in the clindamycin and cephalosporin groups. The small difference in the CRP
levels on day 3 (105 mg/L in the cephalosporin group and 87 mg/L in the clindamycin group) remained non-signiﬁcant (p 0.13 by t-test).
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ated randomization. We do not believe that this has intro-
duced bias, given the similarly of the treatment groups at
baseline.
One patient developed two late infections but, impor-
tantly, he was not a treatment failure. The ﬁrst re-infection
occurred after 17 months—95% of relapses occur within
12 months [23]—and the causative agents differed. Once
infected, an osteoarticular site remains prone to further
infections for some time [24]; an analogy with endocarditis
is evident. No evidence exists that any prolonged medica-
tion would prevent all of these late re-infections [2].
In summary, clindamycin and ﬁrst-generation cephalospo-
rins were shown to be equally effective and safe agents for
treatment of osteoarticular infections of childhood, local
resistance permitting. Even if methicillin-resistant S. aureus is
prevalent, most strains are still clindamycin-susceptible [28],
and clindamycin remains an alternative to newer, but very
expensive, agents [7,29,30]. However, large doses (‡40 mg/
kg daily in four doses, intravenously, then orally) and good
compliance are needed. Normalization of CRP usually allows
discontinuation of antimicrobials. We believe that the treat-
ment of acute osteoarticular infections of childhood can and
should be simpliﬁed, but always taking into account the spe-
ciﬁc needs of an individual patient.
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